AbbVie Inc.
This article is outside of Ballotpedia's coverage scope and does not receive scheduled updates. If you would like to help our coverage scope grow, consider donating to Ballotpedia.
| AbbVie Inc. | |
 | |
| Basic facts | |
| Location: | North Chicago, Ill. |
| Top official: | Richard A. Gonzales, Chairman and CEO |
| Year founded: | 2013 |
| Website: | Official website |
AbbVie Inc., as of 2016, was a global biopharmaceutical company and the producer of Humira, the world's top-selling drug in 2014. The company was based in North Chicago, Illinois.[1]
Background
AbbVie Inc. was established in 2013 as a spinoff of Abbot Laboratories, a global healthcare and pharmaceutical company founded in 1888. AbbVie assumed control of the Abbot Laboratories' pharmaceutical research and development operations while Abbot maintained ownership of its healthcare portfolio, which included medical devices, generic pharmaceuticals, and consumer healthcare products.[3][4]
As a biopharmaceutical research company, AbbVie specialized in the research and development of pharmaceutical products to address the following healthcare areas: immunology, kidney disease, liver disease, neuroscience, oncology, and women’s health. As of 2014, the company's leading product was Humira, a biologic, anti-inflammatory medication that was the best-selling drug worldwide in 2014.[1][5]
AbbVie operated research facilities in the United States, Germany, and Japan as well as drug manufacturing facilities in the United States, Singapore, Italy, Ireland, and Germany. As of October 2016, AbbVie pharmaceutical products were sold in more than 170 countries.[6]
Political activity
Ballot measure activity
AbbVie opposed the 2016 California Drug Price Standards Initiative (Proposition 61), which proposed to regulate drug prices by requiring state agencies to pay the same prices for prescription drugs as the U.S. Department of Veterans Affairs (VA).[2]
Overview of ballot measure support and opposition
The following table details AbbVie's ballot measure stances available on Ballotpedia:
| Ballot measure support and opposition for AbbVie Inc. | |||
|---|---|---|---|
| Ballot measure | Year | Position | Status |
| California Proposition 61, Drug Price Standards (2016) | 2016 | Opposed[2] |  Defeated
|
Leadership
As of 2016, AbbVie Inc. had the following leadership:[7]
- Richard A. Gonzalez, Chairman of the board and chief executive officer
- Laura J. Schumacher, Executive vice president for external affairs, general counsel, and corporate secretary
- William J. Chase, Executive vice president and chief financial officer
- Carlos Alban, Executive vice president for commercial operations
- Michael E. Severino, Executive vice president for research and development and chief scientific officer
- Henry O. Gosebruch, Executive vice president and chief strategy officer
- Timothy J. Richmond, Senior vice president for human resources
- Azita Saleki-Gerhardt, Senior vice president for operations
- Karen Hale, Vice president and chief ethics and compliance officer
- Wulff-Erik Von Borcke, President, Pharmacyclics
Recent news
The link below is to the most recent stories in a Google news search for the terms AbbVie Inc.. These results are automatically generated from Google. Ballotpedia does not curate or endorse these articles.
See also
- California Proposition 61, Drug Price Standards (2016)
- California 2016 ballot measures
- Healthcare policy in California
External links
Footnotes
- ↑ 1.0 1.1 InvestorPlace, "AbbVie Inc (ABBV) Is About to Steamroll the Competition," May 10, 2016
- ↑ 2.0 2.1 2.2 California Fair Political Practices Commission, "November 2016 General Election," accessed October 2, 2016, 2016
- ↑ AbbVie Inc., "Who we are," accessed October 5, 2016
- ↑ Chicago Tribune, "More than splitting pills: Health care giant Abbott Laboratories ready to spin off AbbVie," December 30, 2012
- ↑ AbbVie Inc., "Focus areas," accessed October 5, 2016
- ↑ AbbVie Inc., "Fact sheet," accessed October 5, 2016
- ↑ AbbVie Inc., "AbbVie leadership," accessed October 5, 2016
| |||||||
